Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151418 | 0.95 | CXCR4 (0.57) | SMN1; SMN2KEAP1CXCR4HPGDDUSP3 | |
| SCHEMBL416345 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2KEAP1CXCR4HPGDDUSP3 | |
| Hydrochloric Acid SCHEMBL27141329 | 0.91 | GLA (0.48) | SMN1; SMN2KEAP1CXCR4HPGDDUSP3 | |
| SCHEMBL3158293 | 0.88 | CXCR4 (0.71) | SMN1; SMN2KEAP1CXCR4HPGDDUSP3 | |
| SCHEMBL8614873 | 0.85 | CXCR4 (0.70) | SMN1; SMN2CXCR4HRH3SIGMAR1POLB | |
| SCHEMBL7239607 | 0.85 | KEAP1 (0.71) | SMN1; SMN2KEAP1HPGDDUSP3HRH3 | |
| SCHEMBL10916903 | 0.83 | KDM4E (0.55) | SMN1; SMN2KEAP1HPGDDUSP3HRH3 | |
| Hydrochloric Acid SCHEMBL5570648 | 0.83 | CXCR4 (0.67) | SMN1; SMN2CXCR4HRH3SIGMAR1POLB | |
| SCHEMBL11721752 | 0.83 | CXCR4 (0.74) | SMN1; SMN2CXCR4HRH3SIGMAR1POLB | |
| SCHEMBL21569302 | 0.83 | CXCR4 (0.74) | SMN1; SMN2CXCR4HRH3SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | SMN1; SMN2 1795/4885KEAP1 310/4885CXCR4 2181/4885 |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | SMN1; SMN2 3038/4885KEAP1 252/4885CXCR4 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.